RxDoctor Payments Data

Kalpesh Solanki, DO

Cardiovascular Disease · Ocala, FLNPI 1245325570

Payments from drug & device makers

$53,594in general payments, 2019–2025

Across 652 payments — averaging $82.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$30K
  • Abbott$6K
  • Biotronik Inc.$3K
  • Boston Scientific$2K
  • Amgen$1K
  • Johnson & Johnson$1K
  • plus $10K from 35 others

What the payments were for

  • Travel & lodging$3,94716%
  • Food & beverage$20,34284%
  • Education$550%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,594 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,541,920
Medicare patients
1,352
Services billed
9,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban468$595,040
XareltoRivaroxaban189$244,265
EntrestoSacubitril/Valsartan154$200,632
Repatha SureclickEvolocumab85$94,638
MultaqDronedarone Hcl21$37,641
JardianceEmpagliflozin17$26,578
Repatha SyringeEvolocumab24$24,563
Ranolazine ErRanolazine75$12,512
BrilintaTicagrelor13$7,591
Metoprolol Succinate334$4,223
ClopidogrelClopidogrel Bisulfate338$3,647
Amiodarone Hcl60$3,576
Valsartan75$3,369
Atorvastatin Calcium301$2,996
Diltiazem 24hr Er (Cd)Diltiazem Hcl66$2,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$944$595,040468 claims
Johnson & JohnsonXarelto$1,219$244,265189 claims
NovartisEntresto$647$200,632154 claims
Sanofi-aventis U.S. LLCMultaq$324$37,64121 claims
Boehringer IngelheimJardiance$759$26,57817 claims
AstraZenecaBrilinta$371$7,59113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →